Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Authors
Jean L. Grem
University of Nebraska Medical Center, Omaha, NE
Jean L. Grem , Michael Rothe , Pam K. Mangat , Elizabeth Garrett-Mayer , Maged F. Khalil , Shane O. Rogosin , John Stuart Salmon , Timothy Lewis Cannon , Gina N. Grantham , Susan Halabi , Richard L. Schilsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02693535
DOI
10.1200/JCO.2022.40.4_suppl.106
Abstract #
106
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
First Author: Gordan Srkalovic
Poster
2023 ASCO Annual Meeting
Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Carmen Julia Calfa
Poster
2020 Gastrointestinal Cancers Symposium
Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
First Author: Eyal Meiri